prikaz prve stranice dokumenta Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
  Preuzmi
PDF 196.63 KB
Izlaganje na skupu
Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
Na: 27th Congress of the European Hematology Association. Vienna, Austrija, 2022. https://doi.org/10.1097/01.HS9.0000847308.18096.87
Galušić, Davor; Bašić-Kinda, Sandra; Pijuk, Anđela; Milunović, Vibor; Dreta, Barbara; Franjić, Neven; Coha, Božena; Sinčić-Petričević, Jasminka; Gaćina, Petar; Pejša, Vlatko; Lucijanić, Marko; Aurer, Igor

Citirajte ovaj rad

Galušić, D., Bašić Kinda, S., Pijuk, A., Milunović, V., Dreta, B., Franjić, N. ... Aurer, I. Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases [PowerPoint prezentacija]. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, Davor, et al. "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases." 27th Congress of the European Hematology Association, 09.06.2022.-12.06.2022., Vienna, Austrija. Prezentacija. https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, Davor, Sandra Bašić Kinda, Anđela Pijuk, Vibor Milunović, Barbara Dreta, Neven Franjić, Božena Coha, et al. "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases." Prezentacija sa skupa 27th Congress of the European Hematology Association, Vienna, Austrija, 09.06.2022.-12.06.2022. https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić, D., et al. 'Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases' [Prezentacija], 27th Congress of the European Hematology Association. 09.06.2022.-12.06.2022. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:220:272177

Galušić D, Bašić Kinda S, Pijuk A, Milunović V, Dreta B, Franjić N, i sur.. Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases. [Prezentacija] [pristupljeno 30.10.2024.] Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:272177

D. Galušić, et al., "Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases", prezentirano na: 27th Congress of the European Hematology Association, Vienna, 09.06.2022.-12.06.2022. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:272177

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:272177
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Efficacy and safety of immunochemotherapy in treatment of follicular Nonhodgkin's lymphoma during COVID-19 pandemic: a study of KroHem, the Croatian cooperative group for hematologic diseases
AutorDavor Galušić
AutorSandra Bašić-Kinda
AutorAnđela Pijuk
AutorVibor Milunović
AutorBarbara Dreta
AutorNeven Franjić
AutorBožena Coha
AutorJasminka Sinčić-Petričević
AutorPetar Gaćina
AutorVlatko Pejša
AutorMarko Lucijanić
AutorIgor Aurer
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Increased COVID-19 mortality in patients with lymphoproliferative disorders was observed in this study. Our group of patients had reduced OS and PFS compared to the GALLIUM trial and SARS‐CoV‐2 infection was the most pronounced risk factor for death. Even though in some studies bendamustine has shown to be less toxic and more effective than CHOP in FL, there are some important pandemic aspects that must be considered. Bendamustine exposure seems to be associated with worse outcome in case of the infection with SARS-CoV-2. These intriguing differences could play important role in treatment approach in COVID-19 pandemic. Future studies investigating hematological malignancies in COVID-19 pandemic are warranted.
Jezikengleski
Vrsta recenzijeRecenziran - međunarodna recenzija
DOIhttps://doi.org/10.1097/01.HS9.0000847308.18096.87
URN:NBNurn:nbn:hr:220:272177
Datum izlaganja2022
SkupNaziv: 27th Congress of the European Hematology Association
Kratica: EHA 2022
Lokacija: Vienna, Austrija
Organizator: European Hematology Association
Datum početka: 2022-06-09
Datum završetka: 2022-06-12
Vrsta izlaganja: Postersko izlaganje
URL dokumentahttps://journals.lww.com/hemasphere/Fulltext/2022/06003/P1110__EFFICACY_AND_SAFETY_OF_IMMUNOCHEMOTHERAPY.1000.aspx
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2022-09-07 12:13:27